Cutaneous neuronal nitric oxide is specifically decreased in postural tachycardia syndrome

Julian M. Stewart,1 Marvin S. Medow,1 Christopher T. Minson,2 and Indu Taneja1

1New York Medical College, Valhalla, New York; and 2University of Oregon, Eugene, Oregon

Submitted 23 May 2007; accepted in final form 24 July 2007

Stewart JM, Medow MS, Minson CT, Taneja I. Cutaneous neuronal nitric oxide is specifically decreased in postural tachycardia syndrome. Am J Physiol Heart Circ Physiol 293: H2161–H2167, 2007. First published July 27, 2007; doi:10.1152/ajpheart.00600.2007.—Low flow postural tachycardia syndrome (POTS), is associated with reduced nitric oxide (NO) activity assumed to be of endothelial origin. We tested the hypothesis that cutaneous microvascular neuronal NO (nNO) is impaired, rather than endothelial NO (eNO), in POTS. We performed three sets of experiments on subjects aged 22.5 ± 2 yr. We used laser-Doppler flowmetry response to sequentially increase acetylcholine (ACh) doses and the local cutaneous heating response of the calf as bioassays for NO. During local heating we showed that when the selective neuronal nNOS inhibitor Nω-nitro-L-arginine-2,4-L-diaminobutyric amide (Nω, 10 mM) was delivered by intradermal microdialysis, cutaneous vascular conductance (CVC) decreased by an amount equivalent to the largest reduction produced by the nonselective NO synthesesynthetic enzyme inhibitor nitro-1-arginine (NLA, 10 mM). We demonstrated that the response to ACh was minimally attenuated by nNOS blockade using Nω but markedly attenuated by NLA, indicating that eNO largely comprises the receptor-mediated NO release by ACh. We further demonstrated that the ACh dose response was minimally reduced, whereas local heat-mediated NO-dependent responses were markedly reduced in POTS compared with control subjects. This is consistent with intact endothelial function and reduced NO of neuronal origin in POTS. The local heating response was highly attenuated in POTS [60 ± 6 percent maximum CVC(%CVCmax)] compared with control (90 ± 4 %CVCmax), but the plateau response decreased to the same level with nNOS inhibition (50 ± 3 %CVCmax in POTS compared with 47 ± 2 %CVCmax), indicating reduced nNO bioavailability in POTS patients. The data suggest that nNO activity but not NO of endothelial NOS origin is reduced in low-flow POTS.

METHODS

Subcutaneous neuronal NO (nNO) activity but not NO of endothelial NOS activity, which we assumed to be of endothelial origin (eNO) (28). This conjecture was based on the findings of Kellogg et al. (22, 23) and Minson et al. (29, 30), who demonstrated that local cutaneous heating produced an increase in cutaneous blood flow, which reaches a plateau that is highly sensitive to NO inhibition. However, these investigations used nonisoform-specific NOS inhibition. Whether endothelial NOS (eNOS) or neuronal NOS (nNOS) is primarily involved has not yet been determined in healthy subjects or in POTS patients.

Thus, the goals of the present study were J) to test the hypothesis that nNOS, rather than eNOS, is specifically involved in the local heat response by using a highly selective isoform-specific nNOS inhibitor Nω-nitro-L-arginine methylester (NLA, 2) to investigate the acetylcholine (ACH) dose response to Nω and NLA to demonstrate that eNOS is primarily responsible for the receptor-mediated NO release by ACh, and J) to test the hypothesis that the cutaneous NO deficiency in low-flow POTS is due to decreased production of NO from nNOS [neuronal NO (nNOS)] rather than from eNOS (eNO) using local heating and ACh responses.

POSTURAL TACHYCARDIA SYNDROME (POTS) is identified with chronic orthostatic intolerance (19, 27, 37, 44, 45). POTS is defined by symptoms of orthostatic intolerance associated with an excessive increase in heart rate during orthostatic challenge (37). Symptoms include dizziness, fatigue, exercise intolerance, headache, memory problems, palpitations, nausea, blurred vision, pallor, and abnormal sweating while upright, which improve with recumbence and have no other medical explanation. POTS thus combines symptoms of orthostatic intolerance with findings of excessive upright tachycardia. Stewart and Montgomery (42) previously described a subset of POTS patients designated “low-flow POTS” characterized by generalized pallor and acrocyanosis, often marked by resting as well as upright tachycardia, decreased cardiac output, mild hypovolemia, and widely decreased regional blood flows with severe vasoconstriction. These patients may correspond to subjects studied by other investigators, patients who have reduced blood volume (11, 18), abnormalities of the renin-angiotensin-aldosterone system (35), increased sympathetic outflow measured by microneurography (12), increased plasma angiotensin II (ANG II) (40), and widespread reductions of blood flow in regional circulations (42), including muscle and cutaneous circulation (28, 41).

Microvascular endothelial cell dysfunction has been proposed as a pathophysiological mechanism in POTS (7, 46). The results of prior work from our laboratory, where we used iontophoresis of the nonselective nitric oxide (NO) synthase (NOS) inhibitor Nω-nitro-L-arginine methyl ester (Nω-NAME) and local heating, support the hypothesis of reduced constitutive NO activity, which we assumed to be of endothelial origin (eNO) (28). This conjecture was based on the findings of Kellogg et al. (22, 23) and Minson et al. (29, 30), who demonstrated that local cutaneous heating produced an increase in cutaneous blood flow, which reaches a plateau that is highly sensitive to NO inhibition. However, these investigations used nonisoform-specific NOS inhibition. Whether endothelial NOS (eNOS) or neuronal NOS (nNOS) is primarily involved has not yet been determined in healthy subjects or in POTS patients.

Thus, the goals of the present study were J) to test the hypothesis that nNOS, rather than eNOS, is specifically involved in the local heat response by using a highly selective isoform-specific nNOS inhibitor Nω-nitro-L-arginine methyl ester (NLA, 2) to investigate the acetylcholine (ACH) dose response to Nω and NLA to demonstrate that eNOS is primarily responsible for the receptor-mediated NO release by ACh, and J) to test the hypothesis that the cutaneous NO deficiency in low-flow POTS is due to decreased production of NO from nNOS [neuronal NO (nNOS)] rather than from eNOS (eNO) using local heating and ACh responses.

METHODS

Subjects

POTS patients recruited for the study were referred to the Hypotension Center for investigation of signs and symptoms of chronic orthostatic intolerance lasting at least 3 mon. Orthostatic intolerance was defined by the presence of dizziness, fatigue, exercise intolerance, headache, memory problems, palpitations, nausea, blurred vision, pallor, and abnormal sweating while upright, which were relieved by recumbence and had no other medical explanation. The diagnosis of
POTS was made in these patients during a screening upright-tilt table test to 70° for a maximum of 10 min. POTS was diagnosed by symptoms of orthostatic intolerance during tilt associated with an increase in sinus heart rate of >30 beats/min or to a rate of >120 beats/min during the first 10 min of tilt (27, 36). During the same visit, POTS patients were partitioned on the basis of supine lower limb (calf) blood flow into patients who had decreased blood flow designated as low-flow POTS (<1.2 ml·100 ml tissue⁻¹·min⁻¹) and those that did not. It has been previously shown that POTS patients can be classified into normal-, low-, and high-flow groups based on venous occlusion plethysmography measurements of calf blood flow (41, 42). Our ongoing work indicates that 1.2 ml·100 ml tissue⁻¹·min⁻¹ was the minimum calf blood flow found in healthy volunteers during experiments in more than 75 subjects. We measured calf blood flow by venous occlusion strain-gauge plethysmography (14) while supine. For the current study, patients were retained if they belonged to the low-flow POTS group.

Using these methods, we recruited 13 low-flow POTS patients (all women, Caucasian, and aged 16.6–26.3 yr, with median age of 22.5 yr). Thirteen healthy Caucasian volunteer subjects were also recruited (all women, Caucasian, and aged 17.2–26.9 yr, with median age of 23.6 yr) and were studied after a screening upright tilt at 70° demonstrated normal orthostatic response. Volunteer subjects served as the control group and were recruited from among adolescents and young adults referred for innocent heart murmur. This precluded the participation of subjects with mitral valve prolapse. Subjects with a history of syncope or orthostatic intolerance were specifically excluded.

For all experiments, subjects fulfilled certain criteria. Only subjects free from cutaneous, systemic, and cardiovascular diseases were eligible. Subjects were not taking any medications and refrained from drinking alcohol and caffeinated beverages for 24 h before the study. There were no smokers or trained competitive athletes involved. Informed consent was obtained, and the Committee for the Protection of Human Subjects (Institutional Review Board) of New York Medical College approved all protocols. Women were enrolled without regard to the phase of their menstrual cycle except that none were menstruating during testing procedures.

Protocols

Three sets of experiments were performed in which changes in cutaneous blood flow were measured. The first two sets of experiments investigated the response to local heating in healthy volunteers. The third set of experiments compared the responses to local heating and to ACh in POTS patients with responses in healthy control subjects.

Experiment 1: is nNOS rather than eNOS specifically involved in the local cutaneous heat response? Comparative effects of a highly selective nNOS inhibitor and a nonselective NOS inhibitor on the hyperemia of local heating. Healthy female volunteers (N = 8, all women, Caucasian, and aged 17.0–26.2 yr, with median age of 23.0 yr) were recruited. The ethnicity and age match were constrained by the composition of the POTS population.

We compared the effects of the highly isoform-selective nNOS inhibitor Nω (546.38 Da mol wt) to a maximally plateau-suppressing dose of NLA (219.20 Da mol wt), a nonselective NOS inhibitor. Nω is a highly specific NOS inhibitor that does not bind the inducible NOS isoform and has ~1,528-fold selectivity for nNOS over eNOS (10, 16).

Testing was conducted in a temperature-controlled room (~25°C) at least 4 h after subjects ate a light breakfast. Experiments began after a 30-min acclimatization period, and all experiments were performed while each subject was supine and breathing spontaneously. We used laser-Doppler flowmeters (Perimed, Stockholm, Sweden) and integrating laser-Doppler flow (LDF) probes (Probe 413, Perimed) placed on the lateral aspect of the left calf to measure cutaneous blood flow (20). The LDF probes were surrounded by a heating collar, which enabled localized heating of the area under the flow probe. Measurements were made in the leg because prior experiments from our laboratory consistently indicated significant findings in the lower limb in POTS (17, 41, 43).

Blood pressure was monitored by Finometer (TNO, Amsterdam, The Netherlands), and heart rate was monitored by continuous electrocardiogram. Continuous LDF data were collected at a sampling rate of 200 Hz during experiments multiplexed and interfaced to a personal computer through an analog-to-digital converter (DI-720, DATAQ, Milwaukee, WI) using custom data acquisition software and generating binary files and computer displays of simultaneously collected data from all lasers and blood pressure data.

LDF measurements were made on the left calf while supine with the leg at the level of the heart. Subjects were instrumented with two microdialysis catheters placed at least 6 cm apart and inserted in the dermal space of the lateral aspect of the left calf after gentle hair removal. Each probe (MD-2000 Linear Microdialysis Probes, Bioanalytical Systems, West Lafayette, IN) has a 10-mm microdialysis membrane section that is placed in the intradermal space using a 25-gauge needle as an introducer. Catheters were randomly designated as 1 or 2.

Following placement, catheters were initially perfused with Ringer solution at 2 µl/min. An integrating laser-Doppler flow probe was placed directly over each microdialysis catheter to measure cutaneous LDF. There was a hyperemia following catheter insertion. LDF was recorded until values were similar to those measured over the same area before catheter insertion. The return of LDF to presionetion values usually occurred by 60–90 min (1). When necessary, longer times were allowed until presinsetion LDF was reached.

Once baseline LDF values were obtained, the areas under each laser were gradually heated at 1°C for 10 s to 42°C for at least 30 min until a plateau was reached. Heat was turned off to allow for recovery to baseline LDF. After heat recovery was complete, subjects received perfusate containing 10 mM NLA through catheter 1 and 10 mM Nω through catheter 2 at a rate of 2 µl/min for 30 min. Local heating was repeated until a plateau was established while perfusion with NOS inhibitors continued. At that time, perfusates were switched so that catheter 1 now received Nω while catheter 2 received NLA. Perfusion of catheters continued for 30 additional min. In preliminary studies, we demonstrated that the heat response at a given site is repeatable and that additional perfusion time with NOS inhibitors did not affect the plateau that was reached. Doses of 10 mM NLA and 10 mM Nω were chosen because these were the least concentrations of drugs that gave maximum suppression of the local heating plateau. Nω has a selectivity (K_i ratios) for nNOS/eNOS of 1,538 (10, 16). At the dose used and assuming similar transmicrodialysis transport and interstitial diffusion, this is equivalent to 0.25% of the binding to eNOS and fourfold greater binding to nNOS compared with equimolar NLA. This is discussed more fully in DISCUSSION. However, NLA is a smaller molecule and, therefore, probably reaches higher interstitial vascular concentration in higher concentrations than Nω.

At the end of the experiments, we perfused both catheters with 28 mM sodium nitroprusside to obtain maximum endothelial-independent vasodilation and to compute the maximum cutaneous vascular conductance (CVC_max). Cutaneous vascular conductance (CVC) was calculated as the ratio of LDF to mean arterial blood pressure. CVC_max was defined as CVC during steady sodium nitroprusside infusion. Experimental results were thereafter expressed as %CVC_max (100-CVC/CVC_max).

Experiment 2: what are the relative effects of selective nNOS inhibition compared with nonisoform-specific NOS inhibition during cutaneous ACh dose response? For this purpose we recruited eight healthy female volunteers (all women, Caucasian, and aged 18.5–24.3 yr, with median age of 22.9 yr). The ethnicity and age match were constrained by the composition of the POTS population.

Experiments were performed on a day other than the day of experiment 1. Experiments were not conducted as classical dose-
response and inhibition studies since the derivation of pharmacological characteristics was not our intent. Rather, different doses of agonist (ACh) alone and then combined with NOS inhibitors (NLA and N\textsuperscript{\textregistered}) were used to elicit changes in skin blood-flow responses thought to represent local signaling by NO. We anticipated that NO would not completely suppress the ACh response because there are effects of prostaglandins, endothelium-derived hyperpolarizing factors, and potentially local axon reflexes.

Subjects were instrumented with two microdialysis catheters and integrative laser-Doppler probes as in experiment 1. After recovery, patients had baseline LDF data collected for at least 10 min. Subjects then received perfusate containing 0.01, 0.10, 1.0, 10, and 100 mM ACh dissolved in Ringer solution in ascending doses through each catheter at a rate of 2 \mu l/min. The range of concentration of ACh used (0.01–100 mM) is based on previous determinations in human skin utilizing microdialysis delivery of this agonist (25, 39). LDF monitoring continued, and each dose was administered for 20 min during which steady-state values of LDF were achieved. For purposes of analysis, only the last 5 min of data were averaged during each ACh dose.

Subjects recovered from heat and ACh. Subsequently, each catheter received 10 mM NLA. Local heating was repeated in utilizing microdialysis catheter site fell to baseline values.

Subjects then received perfusate containing 10 mM NLA in catheter 1 and 10 mM N\textsuperscript{\textregistered} in catheter 2 at a rate of 2 \mu l/min while LDF monitoring continued throughout a run-in period for 30 min. Subjects then underwent repeat ACh challenges while maintaining NLA and N\textsuperscript{\textregistered}: (0.01, 0.10, 1.0, 10, and 100 mM ACh) + 10 mM NLA in catheter 1 and (0.01, 0.10, 1.0, 10, and 100 mM ACh) + 10 mM N\textsuperscript{\textregistered} in catheter 2 at a rate of 2 \mu l/min while LDF monitoring continued. Each dose of ACh + blocker was maintained for 20 min. For purposes of analysis, only the last 5 min of data were averaged during the steady state.

At the end of the experiments, both catheters were perfused with 28 mM sodium nitroprusside to obtain CVC\textsubscript{max}.

Experiment 3: is nNO rather than eNO bioavailability reduced in low-flow POTS? Microdialysis data from low-flow POTS patients compared with control subjects: local heating response and the response to ACh. We compared the response of POTS patients and control subjects to two stimuli: ACh, a receptor-mediated endothelium-dependent vasodilator, and local heating. After estimated baseline LDF were measured, two microdialysis catheters were inserted as in experiment 2, and subjects were allowed to recover. Subjects then received perfusate containing 0.01, 0.10, 1.0, 10, and 100 mM ACh dissolved in Ringer solution in ascending doses through catheter 1 and underwent local heating of catheter 2. LDF monitoring continued, and each dose was administered for 20 min during which steady-state values of LDF were achieved. For purposes of analysis, only the last 5 min of data were averaged at each ACh dose.

When these tests were completed, subjects were allowed to fully recover from heat and ACh. Subsequently, each catheter received 10 mM NLA for 30 min after which the response to ACh was measured using the same ascending concentration of ACh (0.1–100 mM) with added 10 mM NLA. Local heating was repeated in catheter 2 while NLA perfusion continued. At the end of the experiments, both catheters were perfused with 28 mM sodium nitroprusside to obtain CVC\textsubscript{max}.

Statistics

We used two-way analysis of variance (2 \times 2) to compare the plateau phases of the local heating response before and after treatment with N\textsuperscript{\textregistered} or NLA in experiment 1. We used analysis of variance with repeated measures to compare dose-response curves of ACh alone, ACh + NLA, and ACh + N\textsuperscript{\textregistered}. We also used two-way ANOVA to compare responses of POTS patients and control subjects with response from varying doses of ACh and to compare means of the plateau phases of local heating in experiment 3. Results were calculated using the statistical package for the social sciences software version 11.0. Apart from representative figures, text, graphic, and Table 1, results are reported as means \pm SE. Significance required \( P < 0.05 \).

RESULTS

Experiment 1: a selective nNOS inhibitor is equally effective as a nonisoform-specific NO inhibitor in blunting the hyperemia of local heating. Results are presented in Figs. 1 and 2. Figure 1 shows a representative heating response before and after NOS inhibition with N\textsuperscript{\textregistered}. Changes in plateau were comparable with those observed before and after NLA. On average, the plateau phase conductance before NLA was 92 \pm 3 \%CVC\textsubscript{max} and after NLA was 47 \pm 5 \%CVC\textsubscript{max} (\( P < 0.001 \)). Similarly, the plateau phase conductance for N\textsuperscript{\textregistered} was 89 \pm 4 \%CVC\textsubscript{max} and after N\textsuperscript{\textregistered} decreased to 44 \pm 3 \%CVC\textsubscript{max} (\( P < 0.001 \)).

There was no significant difference in the effects of NLA or N\textsuperscript{\textregistered} on conductance during heating. We performed a crossover experiment in which the catheter initially receiving NLA was switched to N\textsuperscript{\textregistered} while the catheter receiving N\textsuperscript{\textregistered} was switched to NLA. No change was observed. Figure 2 shows a representative result. There is no difference in the blunted plateau phase or during crossover with either NLA or N\textsuperscript{\textregistered}.

Experiment 2: a selective NOS inhibitor minimally reduces the response to ACh. A nonselective NOS inhibitor greatly reduces the response to ACh. Results are presented in Fig. 3. While NOS inhibition with N\textsuperscript{\textregistered} reduces the dose response to ACh by a small but statistically significant amount (\( P < 0.05 \)), NLA causes a much larger reduction of 50% or greater (\( P < 0.0001 \)). There are thus clear differences in the responses to selective NOS and nonisoform-selective NOS inhibition. These distinguish NO-dependent, endothelial receptor-mediated ACh response from nNOS-mediated ACh responses.

Experiment 3: POTS patients have dose responses to ACh similar to control, but the local heat response is blunted. Resting supine data for POTS patients and control subjects are shown in Table 1. Subjects were similar in size and in arm and leg blood pressure as with control subjects. In POTS patients, supine heart rate was increased (\( P < 0.0025 \)) while pulse pressure was reduced (\( P < 0.05 \)). Resting LDF was signifi-
Heat response in POTS patients (there is a marked decrease in the NO-sensitive plateau of the endothelial responses. On the other hand, as shown in Fig. 5, in POTS. This is consistent with similar receptor-mediated responses to ACh, although there is a trend toward reduced hyperemia when NLA is added. *P < 0.05 compared with ACh alone. †P < 0.05 smaller than control. %CVC, percent cutaneous vascular conductance.

**Fig. 2.** Local heating response at 2 separate microdialysis sites. The site shown in black is perfused for 30 min with nitro-L-arginine (NLA) and then heated to 42°C. After the plateau is reached, NLA is switched for NAw and heating is continued. The site shown in gray is perfused for 30 min with NAw and then heated to 42°C. After the plateau is reached, NAw is switched for NLA and heating is continued. There is similar blunting of the plateau phase at each site and with each NOS inhibitor.

Fig. 3. Dose response of volunteer control subjects to a stepwise increase in acetylcholine (ACh) at 2 separate microdialysis sites. Solid line, response to ACh alone; short-dash line, response to ACh + NAw; long-dash line, response to ACh + NLA. There is a small but significant reduction in overall dose response when NAw is added. There is a much larger attenuation of the dose response when NLA is added. *P < 0.05 compared with ACh alone. †P < 0.05 compared with ACh + NAw.

**Fig. 4.** Dose response of control subjects (black line) and postural tachycardia syndrome (POTS) patients (gray line) to a stepwise increase in ACh at 2 separate microdialysis sites. Both control subjects and POTS patients received ACh alone and combined with NLA. There is no difference between POTS and control results.

**Fig. 5.** Local heating response at 2 separate microdialysis sites. Both control subjects and POTS patients received nitro-L-arginine (NLA) and then heated to 42°C. After the plateau is reached, NLA is switched for ACh alone; short-dash line, response to ACh + NAw; long-dash line, response to ACh + NLA. There is a much larger attenuation of the dose response than control. On average, the plateau was 90 ± 4 %CVCmax for control subjects but only 60 ± 6 %CVCmax for POTS patients.

### DISCUSSION

Summary and Discussion of Findings

Our main findings are as follows.

Administration of a sufficient amount of a nonselective NOS inhibitor blunts the NO-dependent plateau of the local heating response. A selective nNOS inhibitor does an equally good job of blunting at a dose that should exert minimal effect on eNOS. This observation suggests that nNOS is primarily responsible for the increase in bioavailable NO with local heating. Tissue concentrations of drugs delivered by microdialysis are mark-

<table>
<thead>
<tr>
<th>Dimensions and supine hemodynamics</th>
<th>Control</th>
<th>POTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr</td>
<td>22.2 ± 1.1</td>
<td>23.9 ± 0.8</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>61 ± 2</td>
<td>57 ± 2</td>
</tr>
<tr>
<td>Height, cm</td>
<td>170 ± 2</td>
<td>168 ± 3</td>
</tr>
<tr>
<td>Body surface area, m²</td>
<td>1.75 ± 0.04</td>
<td>1.62 ± 0.03</td>
</tr>
<tr>
<td>Supine HR, beats/min</td>
<td>68 ± 2</td>
<td>88 ± 3*</td>
</tr>
<tr>
<td>Supine systolic BP, mmHg</td>
<td>119 ± 3</td>
<td>120 ± 4</td>
</tr>
<tr>
<td>Diastolic systolic BP, mmHg</td>
<td>66 ± 2</td>
<td>71 ± 3</td>
</tr>
<tr>
<td>Pulse pressure, mmHg</td>
<td>58 ± 2</td>
<td>46 ± 3*</td>
</tr>
<tr>
<td>Venous occlusion calf blood flow, ml · 100 ml min</td>
<td>2.5 ± 0.2</td>
<td>0.84 ± 0.11*</td>
</tr>
<tr>
<td>Calf arterial resistance, ml · 100 ml min⁻¹ · mmHg⁻¹</td>
<td>34 ± 4</td>
<td>88 ± 7*</td>
</tr>
<tr>
<td>Maximum laser-Doppler flow with sodium nitroprusside, pfu</td>
<td>177 ± 12</td>
<td>164 ± 18</td>
</tr>
<tr>
<td>Resting laser-Doppler flow, pfu</td>
<td>19.8 ± 1.0</td>
<td>13.4 ± 2.2*</td>
</tr>
<tr>
<td>Resting %CVCmax</td>
<td>13.0 ± 1.0</td>
<td>7.4 ± 1.4*</td>
</tr>
</tbody>
</table>

*C* value smaller than control. %CVC, percent cutaneous vascular conductance.
Combined local heating and ACh dose response suggest a defect in nNO production in low-flow POTS. Microdialysis of ACh produces a similar response in control and low-flow POTS patients, although there is a trend toward a slightly smaller response in POTS. This suggests that NO from eNOS is intact in POTS patients (48). There is a trend toward a reduced ACh response in POTS compared with control, which is consistent with reduced nNO. The local heating response is blunted in POTS compared with control subjects. This suggests that there is a reduction of NO of nNOS origin in low-flow POTS. Taken together, these observations suggest that a defect in NO of nNOS origin accounts for the reduction of NO activity in low-flow POTS.

Significance of Reduced Bioavailable nNO

Initially, nNOS was believed to have primarily neurological as opposed to circulatory effects (31). Subsequently, nNOS has been found in various tissues, including keratinocytes (2), and has great importance for cardiac, skeletal muscle, renal, and neurovascular function (3, 8, 9, 21, 38). Of particular interest are its effects on the sympathetic nervous system, both in the central nervous system and in peripheral nerves (15, 34). It is now believed that nNO helps to regulate central sympathetic outflow and exerts important effects in sympathoexcitiated disease states such as heart failure and hypertension (49, 51). There is a reciprocal relationship between nNO and ANG II (51). It is interesting that ANG II is increased in the plasma of some low-flow POTS patients (40).

nNOS is present within parasympathetic nerves in the peripheral nervous system. It is sometimes colocalized with ACh and vasoactive intestinal peptide in the perivascular parasympathetic fibers (33) and modulates vascular tone and blood flow (32, 47). nNOS is present in skin keratinocytes and could hypothetically be coreleased from cutaneous sympathetic cholinergic nerves. Although we cannot define the specific cell of origin, overall vasoconstriction in low-flow POTS patients (42) would suggest a reduction of nNOS of neural origin.

An Interpretation for the Mechanistic Pathophysiology of Low-Flow POTS Patients

Data from these and other experiments can be tentatively assembled into a unified picture of the pathophysiology of low-flow POTS. Our previous data has shown an increase in ANG II (40) and now a reduction in nNO coupled with peripheral vasoconstriction, reduced cardiac output, and increased total peripheral resistance (42). Increased angiotensin and decreased nitrergic NO act reciprocally to increase central and peripheral sympathoexcitation (50). This is particularly important in states of excessive sympathetic activation such as heart failure (52) in which it appears to be related to oxidative stress (6). Whether a similar sympathoexcitation occurs in low-flow POTS remains to be determined.

Limitations

We studied the cutaneous circulation, which has unique autonomic control. Our recent work indicates that flow regulation abnormalities in low-flow POTS occur throughout the circulatory system and that the local flow abnormalities that occur in skin may be generalized. There is a paucity of quantitative comparisons of local regulatory mechanisms in

Fig. 5. Local heat response of a representative control subject (black line) and a representative POTS patient (gray line). The plateau is decreased in the POTS patient. Administration of NLA once a stable plateau was achieved resulted in a decrease to a similar %CVCmax for both subjects.
humans. However, it is clear that the myogenic response, venoarteriolar reflex, and reactive hyperemia occur in the skin and are abnormal in low-flow POTS patients (41).

We studied the calf cutaneous circulation. Our previous data indicate that flow abnormalities are widespread in low-flow POTS (42). However, whenever peripheral blood flows are studied, the most significant results occur in the lower extremities. It may be that dependence and gravitational exposure are important to observed changes.

Whereas N\textsuperscript{NOS} has well-documented in vitro selectivity for nNOS over eNOS (10, 16), in vivo selectivity has not been well established. Indeed, there could be unexpected actions of this agent on choline transport, acetylcholinesterase, butyryro- ninesterase, muscarinic, prostaglandin, or NO mechanisms other than effects of nitric oxide synthases.

We studied women without regard to menstrual cycle. The phase of the menstrual cycle can exert important effects on NO-dependent mechanisms. However, there is no evidence suggesting a relationship between menstrual cycling and changes in POTS symptoms or signs.

GRANTS
This work was supported by National Heart, Lung, and Blood Institute Grant 5RO1-HL-074873 and National Institute of Diabetes and Digestive and Kidney Diseases Grant 1R21-DK-071647.

REFERENCES